Adverse outcome pathway development II: best practices. - sprookjes - yvandenbroek - TriplyDB

Adverse outcome pathway development II: best practices.

Adverse outcome pathway development II: best practices.

http://www.wikidata.org/entity/Q35055209

about

Exposure to Mixtures of Metals and Neurodevelopmental Outcomes: A Multidisciplinary Review Using an Adverse Outcome Pathway Framework Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes Putative adverse outcome pathways relevant to neurotoxicity Novel adverse outcome pathways revealed by chemical genetics in a developing marine fish A Workflow to Investigate Exposure and Pharmacokinetic Influences on High-Throughput in Vitro Chemical Screening Based on Adverse Outcome Pathways Integrating Publicly Available Data to Generate Computationally Predicted Adverse Outcome Pathways for Fatty Liver.Systems Toxicology: Real World Applications and Opportunities.Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.Adverse outcome pathway (AOP) development I: strategies and principles Accelerating Adverse Outcome Pathway Development Using Publicly Available Data Sources.The Role of Omics in the Application of Adverse Outcome Pathways for Chemical Risk Assessment.Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades Completing the Link between Exposure Science and Toxicology for Improved Environmental Health Decision Making: The Aggregate Exposure Pathway Framework.Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.The adverse outcome pathway (AOP) for chemical binding to tubulin in oocytes leading to aneuploid offspring.Ecdysone Receptor Agonism Leading to Lethal Molting Disruption in Arthropods: Review and Adverse Outcome Pathway Development.The Transcriptome of the Zebrafish Embryo After Chemical Exposure: A Meta-Analysis.Tipping the Balance: Hepatotoxicity and the 4 Apical Key Events of Hepatic Steatosis.Taxonomic applicability of inflammatory cytokines in adverse outcome pathway (AOP) development.Advancing alternatives analysis: The role of predictive toxicology in selecting safer chemical products and processes.Derivation and Evaluation of Putative Adverse Outcome Pathways for the Effects of Cyclooxygenase Inhibitors on Reproductive Processes in Female Fish.Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.Kidney injury biomarkers and urinary creatinine variability in nominally healthy adults.Bayesian integrated testing strategy (ITS) for skin sensitization potency assessment: a decision support system for quantitative weight of evidence and adaptive testing strategy.Adverse outcome pathways: opportunities, limitations and open questions A case study application of the Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) frameworks to facilitate the integration of human health and ecological endpoints for Cumulative Risk Assessment (CRA).Development of the adverse outcome pathway "alkylation of DNA in male premeiotic germ cells leading to heritable mutations" using the OECD's users' handbook supplement.Interpreting Mobile and Handheld Air Sensor Readings in Relation to Air Quality Standards and Health Effect Reference Values: Tackling the Challenges.Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia†Quantitative Adverse Outcome Pathways and Their Application to Predictive Toxicology.From the Cover: Genomic Effects of Androstenedione and Sex-Specific Liver Cancer Susceptibility in Mice.Knotting nets: Molecular junctions of interconnecting endocrine axes identified by application of the adverse outcome pathway concept.Editorial: Special Issue "Effect-related evaluation of anthropogenic trace substances-concepts for genotoxicity, neurotoxicity and endocrine effects".Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Adverse outcome pathways: a concise introduction for toxicologists.Adverse Outcome Pathway Networks II: Network Analytics.Adverse Outcome Pathway Networks I: Development and Applications.

P2860

Q28080575-6B5167AF-03B4-4330-93FE-F7AB83F088B2 Q28389674-1FADA93B-5F7A-4F83-AE7B-46D52CAE18A1 Q28392038-0269FF89-57C6-408F-9C5E-4842076F4AC3 Q28816975-222F376A-FAD1-44D3-8BC2-90A8FF567A16 Q30044590-7F335DC8-316B-4E13-8911-166014B531C0 Q31047871-3E046C84-E72E-487E-AC4F-20358DEA6DA2 Q33577370-04D8265A-6413-4262-97B1-7401C39CB2C7 Q33703437-516C9D0F-275D-4CCE-B9EA-3DBE5E28FF4F Q35055206-80865EAB-F7EE-4BE9-9627-4610F50D430D Q35904173-F96D3A38-B58B-4DC1-BE0F-5452629352A8 Q36376553-CB81C9FA-18B2-49D9-8F10-928419E86A2B Q36764809-114207BD-7696-42AE-B155-73900A071A0F Q36863338-2EE10708-DBEE-45B3-8C0A-01C7A4DC0D99 Q38539524-BA2463D6-BC96-415C-9AC8-BDCB0081B544 Q38595049-C32EEA4F-FFE7-4D8C-B219-3CFF8F5122AC Q38616250-73946466-7E14-4A84-91C5-45D6DCB30FC5 Q38637834-A3B56C6E-19ED-45BE-A145-015C13A4D47A Q38738140-D8E41A71-A8E4-47CE-B3A0-CE50FE251AC5 Q38741447-E0D041B2-8BA6-4186-8AAF-01E83D31E8CB Q38776013-2BD7342A-F8F6-4E25-A3AA-FB1AA1B0D019 Q38903488-4DD17C7A-91D8-42E2-9055-3EA70BB62EEA Q38936122-614F34B8-36CE-471A-9D51-570627ECEE98 Q38959910-4872EEBB-E0DE-4465-83D9-6F5942BCF8CE Q39320908-96D1F025-1145-478F-A2F7-09C83D8DACFC Q40264608-F593DD64-2EDF-43E8-8174-43FAEA9DB52C Q40269161-EEA73C10-3A8C-4A74-9B68-6A2B6661A2BC Q42307037-9CBAE939-3F61-4AE9-8C90-A211D7535F04 Q46242197-F9EA3152-F74E-48DA-BE65-01F889AAAFDB Q46724012-0BF92080-D43D-47F5-9EDF-BFFC95E7B215 Q47096235-C41A95E3-BDE3-44B3-85BB-498C991CB8D5 Q47159009-9A4AC021-F7E0-49F7-A282-3BE81116D463 Q47353535-C48E038C-38FD-43C2-9E0D-753F7597A336 Q47621257-CF2FC546-013D-4B75-B116-7411DD7CC10D Q47688001-D697F49D-EF23-4914-8484-2F2467FED1EB Q47721784-EA1CB53B-FD2D-4F77-99A5-ADB27CD567F3 Q47947469-ABF7C054-CB58-4927-B4E6-BA9F7523201D Q48171351-C8A3368A-A62E-4C0C-8E12-BD25B1B6DA69 Q49800221-2F1D458B-835F-4C06-BF9A-86D54863E535 Q51150402-1466481D-7776-4327-8ED6-D1CD3125AB1D Q51150754-C34EB84B-EBCC-4880-8877-78A1B3EFBCE5

P2860

Adverse outcome pathway development II: best practices.

http://www.wikidata.org/entity/Q35055209

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adverse outcome pathway development II: best practices.

@ast

Adverse outcome pathway development II: best practices.

@en

type

label

Adverse outcome pathway development II: best practices.

@ast

Adverse outcome pathway development II: best practices.

@en

prefLabel

Adverse outcome pathway development II: best practices.

@ast

Adverse outcome pathway development II: best practices.

@en

P1433

Q35055209-3032BB25-31E4-473B-9E14-1B2A1DF0037B

P1476

Q35055209-7FC3B74F-F3D5-41CE-9909-60FA6D08D90C

P2093

Q35055209-126485B5-1FF3-45CE-A316-7D48AACECFA4

Q35055209-15C8C90F-F964-44F6-9DC3-9B9AEE85D37B

Q35055209-42EAE191-E71E-4B5D-AA6A-72FD34EE8B0B

Q35055209-4C9D9F8E-BE27-4B4D-B4BD-EDC40ABD8182

Q35055209-55D76E5A-834F-410A-ABA0-90804C65B9AC

Q35055209-9C88F728-AAC1-4116-90F7-05231FE8A229

Q35055209-BA65D4FD-E530-4ED7-A238-987987B17A0F

Q35055209-BBFFCBC9-5968-4017-B333-281CE4FDEA1A

Q35055209-BF0B8B51-B9F1-412A-A520-4120451C895A

Q35055209-D4A2E0F1-7686-4B32-BA33-2583907C9693

P2860

Q35055209-0B4AD26C-26EA-4C5E-BC3F-B83B412A3AA5

Q35055209-1FCD71CE-4C5C-4646-8460-B1A88A8194B7

Q35055209-2FB7F3F2-FA4B-4D04-B3C1-545398DF1BF9

Q35055209-3F8674FB-6A7C-4175-9A27-284D04BFCFE9

Q35055209-4A657C6C-1335-4843-9A07-F84A77D995D6

Q35055209-5C68E616-3098-4661-B1FF-D98C584D2CFD

Q35055209-66F9EA21-DA70-43CF-9E86-D27F43FC209C

Q35055209-6B91B03A-7A82-44CA-A016-3D96B1BEBBB0

Q35055209-7580BDB1-570F-46DF-B172-043D2C539D32

Q35055209-811B0BC0-F531-44A9-A0F8-E646E8C2043A

P304

Q35055209-FDA14B4E-93D9-4D3B-AA53-334BC6443385

P31

Q35055209-EAC7EAA7-1C87-4010-83AD-79116798702B

P356

Q35055209-D4E455AF-10E8-4881-BD98-636D85710DB0

P433

Q35055209-2C716302-F99E-4625-BF13-B19F72C77415

P478

Q35055209-0E93F79A-E6CC-4A40-9360-9D83D0299274

P50

Q35055209-283A14E6-4F69-4460-997A-61564F867EC4

P577

Q35055209-E62C8596-BDCD-45CF-816C-DD7D08FFC984

P5875

Q35055209-F85009C1-E80A-48F8-BA05-A8FC5B9BB02D

P698

Q35055209-0381F0F9-0610-4035-B8E5-028D54875751

P921

Q35055209-12B614C6-5D72-4CB2-8553-F88F150B5823

Q35055209-C64B3C57-AA3A-4BE2-96FC-E8F6E5744733

P932

Q35055209-6ECDC8A0-269A-401C-AEC8-23DCEAF6E90A

P356

P1433

Toxicological Sciences

P1476

Adverse outcome pathway development II: best practices

@en

P2093

Brigitte Landesmann

http://www.w3.org/2001/XMLSchema#string

Carlie A LaLone

http://www.w3.org/2001/XMLSchema#string

Daniel L Villeneuve

http://www.w3.org/2001/XMLSchema#string

Doug Crump

http://www.w3.org/2001/XMLSchema#string

Malgorzata Nepelska

http://www.w3.org/2001/XMLSchema#string

Markus Hecker

http://www.w3.org/2001/XMLSchema#string

Mary Ann Ottinger

http://www.w3.org/2001/XMLSchema#string

Maurice Whelan

http://www.w3.org/2001/XMLSchema#string

Natàlia Garcia-Reyero

http://www.w3.org/2001/XMLSchema#string

Sharon Munn

http://www.w3.org/2001/XMLSchema#string

P2860

IPCS framework for analyzing the relevance of a noncancer mode of action for humans

Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment

Toxicity testing in the 21st century: a vision and a strategy

Toxicity testing in the 21st century: using the new toxicity testing paradigm to create a taxonomy of adverse effects.

Adverse outcome pathway (AOP) development I: strategies and principles

Screening and testing for endocrine disruption in fish-biomarkers as "signposts," not "traffic lights," in risk assessment.

Allergic contact dermatitis--formation, structural requirements, and reactivity of skin sensitizers.

Alkylation damage by lipid electrophiles targets functional protein systems.

Measurement and estimation of electrophilic reactivity for predictive toxicology.

Progress and promises in toxicogenomics in aquatic toxicology: is technical innovation driving scientific innovation?

P304

321-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TOXSCI/KFU200

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Lucia Vergauwen

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269173290

http://www.w3.org/2001/XMLSchema#string

P698

25466379

http://www.w3.org/2001/XMLSchema#string

P921

adverse outcome pathway

P932

4318924

http://www.w3.org/2001/XMLSchema#string